HASBROUCK HEIGHTS, N.J., March 21 (UPI) -- Nymox Pharmaceutical Corp. in New Jersey said a Phase 2 study of NX-1207 for low-risk localized prostate cancer reported a third positive safety analysis.
The Independent Data Monitoring Committee assessed all patients to date who had received NX-1207 for treatment of their localized prostate cancer. This committee is an arm's length independent body mandated to conduct periodic interim safety reviews at pre-determined stages during the study.
The committee has the authority to recommend changes to the study or to halt the study in the event of unacceptable drug toxicity.
The study tested both low and high doses of NX-1207 for their effect on low-grade localized prostate cancer. In the study, the NX-1207 dose was administered directly into the area of the prostate where the cancer was detected. The procedure was performed by a urologist in an office setting, does not require anesthesia, sedation, or catheterization, takes only a few minutes and involves minimal discomfort to the patient, the company said.
NX-1207 was also in late stage Phase 3 development in the United States for the treatment of benign prostatic hyperplasia -- prostate enlargement -- a common condition of older men, the company said.